These findings indicate that METTL1 regulates a metabolism–epigenetic–immune axis, promoting tumor proliferation and metabolic reprogramming while modulating CD155-mediated immune escape, suggesting a potential intervention target for CRC immunotherapy. Here, PVR is linked to colorectal carcinoma.